期刊论文

Feng, S.

中文

中国肿瘤临床

1000-8179

2012

39

5

259-262

10.3969/j.issn.1000-8179.2012.05.005

本文课题受湖南省自然科学基金（编号：10JJ6046）资助

本校为第一且通讯机构

目的:评价PCR-SSCP筛检非小细胞肺癌(NSCLC)EGFR基因突变的临床应用潜力.方法:分别采用DNA测序法和PCR-SSCP分析对一定数量的NSCLC标本进行EGFR基因突变检测,以DNA测序结果为金标准,计算PCR-SSCP法的灵敏度、假阴性率、特异度、假阳性率、约登指数、粗符合率、预测值和似然比等指标;同时随机抽取20%的样本,重新进行PCR-SSCP分析,计算两次结果的Kappa指数值.结果:PCR-SSCP分析的灵敏度为97.2%,假阴性率为2.8%,特异度为94.3%,假阳性率为5.7%,约登指数为0.915,粗符合率为94.8%,阳性预测值为77.8%,阴性预测值为99.4%,阳性似然比为17.1,阴性似然比为0.5,前后两次PCR-SSCP分析的Kappa指数值为0.81(P

Objective: To evaluate the clinical application potentiality of PCR-single strand conformation polymorphism (PCR-SSCP)used to screen EGFR mutations in non-small cell lung cancer(NSCLC). Methods: Certain NSCLC specimens were tested with PCR-SSCP analysis and DNA sequencing respectively, and then some related indices were calculated, such as sensitivity, false negative rate, specificity, false positive rate, Youden index, crude agreement rate, likelihood ratio, and predictive value, taking the results of DNA sequencing as the "gold standard". At the same time, 20% of the tested specimens were ra...